On April 29, 2022 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, reported that its current U.S. Federal Supply Schedule (FSS) contract with the Veterans Health Administration (VHA) has been expanded to include coverage for the Company’s entire skin cancer test portfolio, effective as of April 15, 2022 (Press release, Castle Biosciences, APR 29, 2022, View Source [SID1234613241]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Castle’s innovative tests for skin cancer provide precise, personalized information based on each patient’s tissue biology and are designed to meaningfully impact how skin cancers are diagnosed and managed," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We are proud that veterans and their families treated at VHA and Military Health System (MHS) medical centers will now have greater access to our skin cancer tests and the clinically actionable information they provide, which can help guide and improve the management of their disease."
One in five Americans will be diagnosed with skin cancer during their lifetime, making it the most common form of cancer in the U.S.1 U.S. military personnel have higher rates of skin cancer than civilians, due in part to occupational sun exposure and other work conditions, compounded by certain demographic characteristics associated with higher rates of melanoma.2
The VHA is a component of and implements the healthcare program for U.S. veterans through the U.S. Department of Veterans Affairs (VA). Castle’s current five-year FSS contract went into effect on Aug. 15, 2021, and included coverage for the Company’s DecisionDx-Melanoma gene expression profile test. Effective April 15, 2022, the expanded contract includes coverage for the remaining four tests in Castle’s dermatologic cancer test portfolio: DecisionDx-SCC, DecisionDx DiffDx-Melanoma, myPath Melanoma and DecisionDx-CMSeq. Castle’s expanded FSS contract provides greater access to the aforementioned tests for veterans being treated through the VHA, the largest integrated health care system in the U.S., as well as active-duty service members and their families seeking medical treatment through the MHS.
More information about Castle’s tests can be found at www.CastleTestInfo.com.